This note demonstrates how using HTRF to quantify human IFNγ is a powerful and effective approach for the functional characterization of anti-PD1/PDL1 antibodies. Complementary to a real-time live-cell imaging approach, the HTRF-based IFNγ assay delivers fast and accurate results, boosting immuno-oncology drug discovery programs.
We are committed to your privacy. Revvity needs the contact information you provide us to keep you aware about relevant content, products, and services. You may unsubscribe from these communications at any time. For more information check out our Privacy Policy.
©2023 Revvity - All rights reserved